Home/Pipeline/Prasinezumab

Prasinezumab

Parkinson's Disease

Phase 2bActive

Key Facts

Indication

Parkinson's Disease

Phase

Phase 2b

Status

Active

Company

Prothena

About Prothena

Prothena Corporation plc is a Nasdaq-listed biotech firm focused on discovering and developing transformative antibody therapies for diseases driven by protein misfolding, including Parkinson's disease and ATTR amyloidosis. The company's strategy is built upon a foundational scientific legacy from Athena Neurosciences and Elan, which has yielded key discoveries in amyloid biology and led to commercial products like Tysabri. Prothena advances a mix of wholly-owned and partnered clinical-stage assets, targeting high-need neurological and rare disease markets with significant unmet medical need. Its core competency lies in designing antibodies that selectively target pathogenic forms of proteins to modify disease progression.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Rare Peripheral Amyloid Diseases

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active